These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8843280)

  • 1. Mechanism of differential activities of ofloxacin enantiomers.
    Morrissey I; Hoshino K; Sato K; Yoshida A; Hayakawa I; Bures MG; Shen LL
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1775-84. PubMed ID: 8843280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
    Hilliard JJ; Krause HM; Bernstein JI; Fernandez JA; Nguyen V; Ohemeng KA; Barrett JF
    Adv Exp Med Biol; 1995; 390():59-69. PubMed ID: 8718602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.
    Wolfson JS; Hooper DC; Ng EY; Souza KS; McHugh GL; Swartz MN
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1861-3. PubMed ID: 2829717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.
    Hoshino K; Sato K; Akahane K; Yoshida A; Hayakawa I; Sato M; Une T; Osada Y
    Antimicrob Agents Chemother; 1991 Feb; 35(2):309-12. PubMed ID: 1850968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of quinolones against Escherichia coli DNA gyrase.
    Yoshida H; Nakamura M; Bogaki M; Ito H; Kojima T; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1993 Apr; 37(4):839-45. PubMed ID: 8388200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
    Tanaka M; Sato K; Kimura Y; Hayakawa I; Osada Y; Nishino T
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1489-91. PubMed ID: 1656864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor.
    Nakada N; Gmünder H; Hirata T; Arisawa M
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1966-73. PubMed ID: 7811004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
    Wu P; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris.
    Ishii H; Sato K; Hoshino K; Sato M; Yamaguchi A; Sawai T; Osada Y
    J Antimicrob Chemother; 1991 Dec; 28(6):827-36. PubMed ID: 1667782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of inhibition of DNA gyrase by ES-1273, a novel DNA gyrase inhibitor.
    Oyamada Y; Yamagishi J; Kihara T; Yoshida H; Wachi M; Ito H
    Microbiol Immunol; 2007; 51(10):977-84. PubMed ID: 17951987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
    Heddle JG; Lu T; Zhao X; Drlica K; Maxwell A
    J Mol Biol; 2001 Jun; 309(5):1219-31. PubMed ID: 11399091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofloxacin, a bactericidal antibacterial.
    Smith JT
    Chemotherapy; 1991; 37 Suppl 1():2-13. PubMed ID: 1646700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
    Revel-Viravau V; Truong QC; Moreau N; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2054-61. PubMed ID: 8878580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique biological properties and molecular mechanism of 5,6-bridged quinolones.
    Macinga DR; Renick PJ; Makin KM; Ellis DH; Kreiner AA; Li M; Rupnik KJ; Kincaid EM; Wallace CD; Ledoussal B; Morris TW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2526-37. PubMed ID: 12878515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action of the new quinolones: new data.
    Hooper DC; Wolfson JS
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
    Barnard FM; Maxwell A
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1994-2000. PubMed ID: 11408214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.
    Takahata M; Nishino T
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1192-5. PubMed ID: 2847648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.